Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2, along with other therapeutic compounds, announces a strategic investment from Sanofi. Under the terms of the agreement, Sanofi receives a right of first negotiation to license compounds across various indications, including immunological and metabolic syndrome indications, driving the momentum behind ROCK2 inhibitor treatments. ROCK2 is an effector of the small GTPase Rho and belongs to the AGC family of kinases. It is implicated in the pathology of multiple diseases, including metabolic, autoimmune, inflammatory, and neurologic disorders for which there is either inadequate or no treatment at all.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- SNY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Regeneron, Sanofi say FDA approves Dupixent for pediatric patients
- Inhibrx to sell INBRX-101 to Sanofi in $2.2B transaction
- Sanofi initiated with an Equal Weight at Morgan Stanley
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
